New TherapyLong-Acting Basal Insulins A Review of the More Recently Approved AgentsGallegos Aragon, Kelsea PharmD*; Elmaoued, Amre Adel PharmD†; Pham, Ngoc-Yen T. PharmD†; Conklin, Jessica R. PharmD*; Ray, Gretchen M. PharmD*Author Information From the *University of New Mexico College of Pharmacy, Department of Pharmacy Practice and Administrative Sciences, Albuquerque, NM †University of New Mexico Hospital, Department of Pharmacy, Albuquerque, NM. Disclosure: The authors have no conflicts of interest to report. Correspondence: Gretchen M. Ray, PharmD, University of New Mexico College of Pharmacy, Department of Pharmacy Practice and Administrative Sciences, MSC09 5360, 1 University of New Mexico, Albuquerque, NM 8731. E-mail: [email protected]. Cardiology in Review: September/October 2019 - Volume 27 - Issue 5 - p 260-266 doi: 10.1097/CRD.0000000000000266 Buy Metrics Abstract Long-acting basal insulins are used for the management of both type 1 and type 2 diabetes mellitus. Long-acting basal insulins were developed utilizing recombinant DNA technology and have been available since 2000 with the approval of insulin glargine U-100 followed by insulin detemir in 2005. In recent years, diabetes management has become more complex with the approval of insulin glargine U-300 and insulin degludec U-100 and U-200. Both insulin glargine U-300 and insulin degludec have been compared with insulin glargine U-100 and have demonstrated longer durations of action, as well as lower rates of hypoglycemia. This review discusses the Food and Drug Administration-approved long-acting insulins with a focus on recently approved agents and their efficacy and safety compared with the first long-acting basal insulins. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.